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Antibody responses are often considered to play only a limited role in controlling viremia during chronic infections with
human or simian immunodeficiency virus (SIV). We investigated this by determining the effect of passively infused antibody
on plasma viremia in infected rhesus macaques. The emphasis of the study was to understand the mechanism(s) underlying
any observed effects. We infused serum immunoglobulins (SIVIG) purified from SIVmac251-infected macaques into other
SIVmac251-infected macaques. The rapid progressor recipients had high viral loads but negligible titers of antibodies to SIV.
Thus, we could significantly increase antibody titers with exogenous SIVIG. Despite restoring anti-SIV titers to levels typical
of macaques with a normal disease course, SIVIG had only a modest effect on plasma SIV RNA and cell-associated viral load;
the maximum, transient, reduction was threefold. The decrease in plasma RNA commenced within 1–2 h of SIVIG infusion,
the nadir was at 12 h, and then a rebound occurred. A two- to threefold drop in cell-associated viral RNA was simultaneous
with the decrease in plasma RNA. The kinetics of the viremia changes are inconsistent with neutralization of new cycles of
infection. More likely, perhaps unexpectedly, is that infused antibodies killed SIV-infected cells, via an effector mechanism
such as antibody-dependent cellular cytotoxicity. © 2000 Academic Press
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Infection of humans with human immunodeficiency
virus type 1 (HIV-1), or macaques with simian immuno-
deficiency viruses (SIV), induces vigorous, sustained im-
mune responses to multiple viral antigens (Desrosiers,
1995; Burton and Moore, 1998; Letvin, 1998; Nathanson
et al., 1999). Thus, antibodies are raised against struc-
tural components of the viruses (Allen et al., 1985; Moore
t al., 1994; Binley et al., 1997; Parren et al., 1997, 1999),
and cytotoxic T-lymphocyte (CTL) and T-helper cells that
recognize multiple epitopes are generated (Koup et al.,
1994; Ogg et al., 1998; Rosenberg et al., 1998; Kuroda et
al., 1999; Pitcher et al., 1999). Some control is thereby
established by the immune system over the extent of
HIV-1 or SIV replication, at least for several years (Letvin,
1998; McMichael and Phillips, 1998). There is now very
good evidence that the CD81 T-cell response, probably
ominated by CTL activity, has a powerful influence on
imiting the extent of viral replication (Ogg et al., 1998;
chmitz et al., 1999). However, there is rather less sup-
ort for any decisive impact of the antibody response on
1 To whom correspondence and reprint requests should be ad-
ressed at The Aaron Diamond AIDS Research Center, 455 First Ave-s
T
ue, New York, NY 10016. Fax: (212) 725-1126. E-mail: jmoore@
darc.org.
237IV-1 or SIV replication, especially once the infection has
ecome fully established in the host (Foresman et al.,
998; Parren et al., 1999). Indeed, even the most potent
eutralizing antibodies thus far identified have little effect
n HIV-1 replication when given to hu-PBL SCID mice
uring established infection (Poignard et al., 1999). Con-
istent with this finding, the administration of immune
erum containing anti-HIV-1 polyclonal antibodies
HIVIG) has generally had little impact on established
nfection in chimpanzees or humans (Jacobson et al.,
993, 1994; Levy et al., 1994; Vittecocq et al., 1995; Lam-
ert et al., 1997; Mofenson et al., 1999).
To further address what effect (if any) antibodies can
ave during chronic lentiviral infection, and by what
echanism, we have undertaken passive immunization
tudies in a subset of macaques chronically infected
ith SIVmac251. A proportion (8 of 33 infected animals, or
4%; Smith et al., 1999) of macaques infected with this
irus soon develop very high, sustained plasma viral
oads and progress rapidly to AIDS and death (Desro-
iers, 1995; Folks et al., 1997; Steger et al., 1998; Dykhui-
en et al., 1999; Lu et al., 1999; Reimann et al., 1999;
athanson et al., 1999; Yin et al., 1999). These “rapid
rogressors” never develop a sustained antibody re-
ponse to the infecting virus, probably because too much
-helper function is destroyed during acute infection
0042-6822/00 $35.00
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238 BINLEY ET AL.(Rosenberg et al., 1998; Steger et al., 1998). A useful feature
of these animals is that their minimal or nonexistent level of
endogenous anti-SIV antibodies allows us to significantly
increase the total anti-SIV titers, by exogenous infusion of
antibodies purified from animals that develop normal anti-
body responses to SIV (SIVIG). Such an increase cannot be
achieved when HIVIG is provided to HIV-1-infected humans
with a “normal” seroconversion profile; only a small pertur-
bation of endogenous antibody titers occurs after exoge-
nous HIVIG infusion, which limits what can be concluded
about the mechanisms by which antibodies might modu-
late viral load (Moore, 1998).
Here, we report the effect of SIVIG infusion on plasma
SIV RNA and cell-associated viral load in rapidly pro-
gressing, SIVmac251-infected monkeys. The exogenous
ntibodies, despite increasing total antibody titers
gainst the viral structural proteins, caused only small
nd transient reductions in plasma viremia by a mecha-
ism that was inconsistent with virus neutralization but
hich may be effector-mediated. There was, as antici-
ated, no clinical benefit to SIVIG infusion.
RESULTS
roperties of purified SIVIG
Two SIVIG preparations were derived from pooled
lasma from SIVmac251-infected macaques. One RhIG
TABLE 1
Properties of Purified IgG Stocks
IgG prep
Concentration
(mg/ml)
Anti-gp120
titer
Anti-p27
titer
50% neutralization
titer (mg/ml)
SIVIG-1 15.0 68,000 31,000 1.15
SIVIG-2 16.0 170,000 30,000 0.60
RhIG 12.8 ,100 ,100 .100
Note. Column 1, stock designation; column 2, IgG concentration in
mg/ml; column 3, midpoint anti-gp120 binding antibody titer; column 4,
midpoint anti-p27 binding antibody titer; column 5, concentration in
mg/ml required to achieve 50% protection from virus-induced cell killing
using TCA SIVmac251 in CEMx174 cells.
T
Summary of SIV
Animal Status
Weight
(kg)
Preinfusion
viral load
(bDNA/ml)
IgG prep
infused
Amou
IgG in
(m
1356 Rapid progressor 7.5 2.1 3 107 SIVIG-1 12
191N Rapid progressor 6.5 2.8 3 107 SIVIG-2 11
1504 Rapid progressor 4.5 4.6 3 107 RhIG 7
R341 Normal progressor 7.3 6.7 3 105 RhIG 12
Note. Column 1, designation of animal; column 2, disease status of an
of infusion; column 5, IgG preparation used for infusion; column 6, am
8, time elapsed during infusion; column 9, midpoint anti-gp120 titer preinfusion
11, day of infection relative to day of infusion (day 0); column 12, day of euthatock (control IgG) was purified from the plasma of un-
nfected macaques. The IgG concentrations, anti-gp120
nd anti-Gag antibody titers, and neutralization titers
gainst tissue-culture adapted SIVmac251 are recorded
for each preparation in Table 1. The similarities in the
characteristics of the different SIVIG preparations sug-
gest that the use of more than one preparation in these
experiments, which was necessitated by considerations
of supply, does not introduce a significant variable.
As a frame of reference, mature binding antibody titers
to gp120 in macaques infected with SIVmac251 that un-
dergo a typical disease course range from 1:50,000 to
1:300,000 (Connor et al., 1998). Neutralizing antibody
titers to tissue culture-adapted (TCA) SIVmac251 are usu-
ally in the range of 1:2000 to 1:30,000 in such animals
(Montefiori et al., 1996; Langlois et al., 1998). However,
eutralizing titers against primary viruses from the ma-
aque host are frequently negligible when measured in
itro (see below). In contrast, macaques with a rapidly
rogressive disease course fail to sustain (or develop)
ignificant titers of binding antibodies to SIV structural
roteins, and they lack neutralizing antibodies (Steger et
l., 1998; Dykhuizen et al., 1999; Lu et al., 1999; Reimann
t al., 1999).
ffect of SIVIG infusion on anti-SIV titers and viral
oad: Monkeys 1356 and 191N
These experiments were designed to evaluate what
appens when sufficient SIVIG is infused into rapidly
rogressing macaques to transiently restore antibody
iters in these animals to the levels found in animals with
more typical disease course. The use of rapid progres-
ors with low endogenous antibody titers to SIV antigens
llowed us to significantly perturb the preexisting anti-
ody concentration and monitor the effects this had on
iral load. We neither expected, nor observed, any clini-
al benefit or increased life-span from the SIVIG infusion
Table 2; and see Smith et al., 1999).
Two different preparations of SIVIG were infused into
wo rapid progressors (animals 1356 and 191N). At the
RhIG Infusions
mg IgG/kg
animal
Infusion
time
(min)
Preinfusion
anti-gp120
titer
Postinfusion
anti-gp120
titer
Day of
infection
Day of
death
170 17 2000 100,000 2745 113
170 12 2200 48,000 2153 34
170 15 770 1400 2132 58
170 6 140,000 130,000 2124 331
olumn 3, weight of the animal in kg; column 4, plasma SIV RNA at time
infused IgG; column 7, amount of IgG infused per kg animal; columnABLE 2
IG and
nt of
fused
g)
75
08
65
41
imal; c
ount of; column 10, midpoint anti-gp120 titer immediately postinfusion; column
nization relative to day of infusion (day 0).
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239ANTIBODY INFUSION OF SIV-INFECTED MONKEYStimes of SIVIG infusion, plasma viremia levels were very
high in both macaques, at 2.1 3 107 and 2.8 3 107 RNA
opies/ml (Table 2, Figs. 1 and 2). The endogenous titers
f anti-gp120 binding antibodies were low (around
:2000), and the anti-p27 titers were ,1:100 (Figs. 1 and
).
Macaque 1356 received SIVIG-1 at 170 mg/kg, a total
f 1275 mg (Table 2). This was sufficient to elevate the
nti-gp120 titer to 1:100,000 (Table 2, Fig. 1A). Titers to
27 were also sharply elevated, to 1:29,000. Thus, the
dministration of SIVIG restored the anti-gp120 titer in
his rapid progressor to a level comparable with those in
nimals that sustain normal titers of antibodies to
IVmac251 antigens (Connor et al., 1998). Over time, the
nti-gp120 and anti-p27 titers gradually decayed, with
alf-lives of approximately 13 and 7 days, respectively
Fig. 1A). Neutralizing antibody titers to TCA SIVmac251
increased by approximately threefold to 1:3200, a titer at
the low end of the range observed in normal progressors
(Fig. 1B). However, the primary viruses from both SIVIG-
infused animals were not neutralized to the same extent
in these assays (see below). The neutralization-sensitive
TCA SIVmac251 virus is convenient for comparing anti-
body titers among plasma samples from different ma-
FIG. 1. Effect of SIVIG infusion on anti-SIV titers and viral load:
monkey 1356. Monkey 1356 was infused with SIVIG-1 at time 0. (A)
Anti-gp120 (E) and anti-p27 () binding antibody titers. (B) Neutraliza-
tion titers against TCA SIVmac251. (C) Plasma SIV RNA level. (D) Cell-
associated plasma viremia, recorded in relative units of multiply
spliced RNA (msRNA).caques, but it is not suitable for quantitation of in vivo
antibody potency.Within 1–2 h of SIVIG infusion into macaque 1356,
there commenced a small but consistent decline in
plasma SIV RNA (Fig. 1B). The viral load nadir, an ap-
proximately twofold reduction, was reached at about 12 h
postinfusion; the half-life of the decline was estimated to
be 10 h. A gradual increase in plasma viremia then took
place over the next few days, until a level comparable
with that existing prior to SIVIG infusion was achieved
(Fig. 1C; and data not shown). The amounts of cell-
associated SIV RNA were measured in samples of pe-
ripheral blood mononuclear cells (PBMC) at the same
time points as the plasma SIV RNA determinations. In
general, the profiles of changes in the plasma SIV RNA
levels and in cell-associated viral loads were very similar
(Fig. 1D).
The above experiment was repeated with a second
rapidly progressing macaque (191N), infected with the
same SIVmac251 stock. This animal received 170 mg/kg of
IVIG-2, sufficient to elevate the anti-gp120 titer from its
aseline value of 1:2200 to a peak of 1:48,000 (Table 2,
ig. 2A). This anti-gp120 titer increase was about half
hat achieved in macaque 1356, although the peak titer
as again comparable to those seen in SIVmac251-in-
fected macaques with normal disease courses. Com-
pared to animal 1356, a much larger increase in neutral-
izing antibody titer, from 1:34 to 1:5030 against TCA
SIVmac251, occurred in animal 191N after SIVIG infusion
FIG. 2. Effect of SIVIG infusion on anti-SIV titers and viral load:
monkey 191N. Monkey 191N was infused with SIVIG-2 at time 0. (A)
Anti-gp120 (E) and anti-p27 () binding antibody titers. (B) Neutraliza-
tion titers against TCA SIVmac251. (C) Plasma SIV RNA level. (D) Cell-
associated plasma viremia.
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240 BINLEY ET AL.(Fig. 2B), since baseline preinfusion titers in this animal
were particularly low.
The changes in plasma viremia in animal 191N after
SIVIG-2 infusion were similar to those that took place in
macaque 1356 after SIVIG-1 infusion. Thus, a gradual
decline in plasma viremia had commenced in animal
191N by 1 h postinfusion, and a nadir was reached by
approximately 12 h, when plasma viremia was about
threefold less than the preinfusion level. However, this
reduction was again not sustained, and plasma viremia
levels had returned to almost the preinfusion levels
within 48 h (Fig. 2C). Again, the changes in cell-associ-
ated viral load closely mirrored those in plasma SIV RNA
levels (Fig. 2D).
The effectiveness of SIVIG at altering the rate of virion
clearance from plasma is recorded in Table 3. For mon-
keys 1356 and 191N, the plasma virus clearance rates at
12 h postinfusion were increased by 27 and 47%, respec-
tively. If the preinfusion half-life of plasma virions is
conservatively assumed to be 2 h (Ramratnam et al.,
1999), then SIVIG infusion caused 2.3 3 107 and 5.5 3
107 extra viral particles to be removed from the plasma of
he two animals over this 12-h period (Table 3). If the
irion half-life is taken to be 10 min (Igarashi et al., 1999;
hang et al., 1999), then about 10 times more viral parti-
les were cleared during that period.
There may be a dose-dependency to the transient,
wo- to threefold reductions in plasma viremia after SIVIG
nfusion; these reductions were measured in two of two
acaques receiving high-dose SIVIG (Figs. 1 and 2), but
ot in another macaque (AR73) that received a 2.6-fold
ower dose of 65 mg/kg of SIVIG-3 (data not shown).
eak anti-gp120 titers of 1:100,000 (macaque 1356) and
:48,000 (macaque 191N) were associated with a 2- to
-fold reduction in plasma viremia, whereas a titer of
:7500 (macaque AR73) was found when there was no
TABLE 3
Viral Clearance Following IgG Infusion
Animal
% increase in
viral clearance Total clearance
1356 (SIVIG-1) 27 2.3 3 107
191N (SIVIG-2) 47 5.5 3 107
1504 (RhIG) 23 25.7 3 106
R341 (RhIG) 243 21.2 3 106
Note. The percentage increase of virion clearance in the first 12 h
after antibody infusion and the total clearance of virus particles due to
antibody infusion are calculated assuming a free virion half-life of 2 h
(Ramratnam et al., 1999). Details of the calculation are given under
Materials and Methods. If the free virion half-life is on the order of 10
min (Igarashi et al., 1999; Zhang et al., 1999), then the total clearance of
virions would increase by a factor of 10.etectable change in viral load. The unavoidably small
umber of animals in the study does, however, limit the
v
3trength of any conclusions about the quantitative rela-
ionship between virion clearance and antibody titers.
eutralization of primary SIV isolates
The abilities of pre- and postinfusion plasma samples
rom each monkey to neutralize SIVmac251 primary vi-
uses isolated from macaques 1356 and 191N were as-
essed using macaque PBMC. For each plasma sample,
he primary virus neutralization titer was very low or
egligible, which is consistent with previous reports that
rimary SIVmac251 isolates are strongly resistant to neu-
tralization by autologous or heterologous plasma (Lang-
lois et al., 1998; Means et al., 1997). The failure of the
plasma samples to neutralize primary isolates meant
that the dynamic range of the assay was too small to
accurately measure any changes in titers caused by
SIVIG infusion. To gauge the magnitude of such
changes, we therefore performed additional neutraliza-
tion assays using TCA SIVmac251 viruses in CEMx174
cells (Figs. 1 and 2). We fully appreciate that neutralizing
antibody titers against TCA viruses are not related to the
strength of virus neutralization in vivo (Moore and Ho,
1995).
Isolate 1356 resisted neutralization by SIVIG-1 (IC50 .
36 mg/ml), and by pre- and posttreatment plasma sam-
ples (IC50 , 1:4 dilution), measured in CEMx174 cells.
solate 191N resisted neutralization in human PBMC by
IVIG-2 (IC50 . 1600 mg/ml) and by pre- and postinfusion
lasma (IC50 , 1:5 dilution), but it was neutralized weakly
in CEMx174 cells by SIVIG-2 (IC50, 86 mg/ml) and by
postinfusion plasma samples (IC50 at 0 h 5 ,1:5; at 1 h
5 1:111; at 3 h 5 1:77; and at 24 h 5 1:7). Low neutral-
ization titers measurable in CEMx174 cells that are not
detected in PBMC are not considered to be particularly
potent (Langlois et al., 1998).
Effect of control Ig (RhIG) on anti-SIV titers and viral
load: Monkeys 1504 and R341
To control for nonspecific effects of antibody infusion,
we prepared RhIG from an uninfected rhesus macaque
and infused this at 170 mg/kg into two SIVmac251-infected
onkeys, 1504 and R341 (Table 2, Figs. 3 and 4). Monkey
504 was a rapid progressor, comparable in its disease
ourse to animals 1356 and 191N, whereas monkey R341
as undergoing a more typical disease course and so
ad a lower viral load and a high anti-gp120 titer (Table
). The RhIG infusions had no significant effect on anti-
IV binding or neutralizing (to TCA SIVmac251) antibody
iters in either animal (Figs. 3A, 3B, 4A, and 4B). A modest
ncrease in plasma viremia was noted in animal R341
oon after RhIG infusion, the cause of which is unknown
Fig. 4C). However, plasma viremia was otherwise stable
n both RhIG-infused animals, within the limits of assay
ariations, over the duration of the experiments (Figs. 3C,
D, and 4C). Primary virus isolated from macaque 1504
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241ANTIBODY INFUSION OF SIV-INFECTED MONKEYSresisted neutralization in human PBMC by all pre- and
postinfusion plasma samples from animal 1504 (IC50 ,
:5 dilution).
omparison of plasma SIV RNA and cell-associated
iral load
Direct comparison of the changes in plasma SIV RNA
nd cell-associated viral load in monkeys 1356 and 191N
SIVIG recipients) and 1504 and (RhIG recipient) shows
hat the transient reductions in plasma viremia associ-
ted with SIVIG infusion are unlikely to be nonspecific
ffects of the infusion procedure itself (Fig. 5). Further-
ore, the initial, transient declines in SIV RNA levels in
he plasma and cells clearly occur in concert in the two
IVIG-infused animals (Figs. 5A and 5B). Calculations of
he percentage changes in virion clearance over the first
2 h postinfusion revealed that net decreases in the
learance rate of 3 and 43% occurred in control animals
504 and R341, respectively. This contrasts markedly with
he 30–50% increases in the SIVIG-infused animals (Ta-
le 3).
ffect of SIVIG infusion on circulating CD41 and
D81 T-cell counts
The infusions of SIVIG into monkeys 1356 and 191N,
FIG. 3. Effect of RhIG on anti-SIV titers and viral load: monkey 1504.
Monkey 1504 was infused with RhIG at time 0. (A) Anti-gp120 (E) and
nti-p27 () binding antibody titers. (B) Neutralization titers against TCA
IVmac251. (C) Plasma SIV RNA level. (D) Cell-associated plasma vire-
ia.nd of RhIG into monkey 1356, were associated with
apid, significant reductions in the circulating counts ofoth CD41 and CD81 T cells (Fig. 6). These counts
returned to approximately baseline values after 8, 3, and
.20 days in animals 1356, 191N, and 1504, respectively.
Since the T-cell count reductions occurred in the RhIG-
infused control monkey as well as in the SIVIG-infused
animals, it is unlikely that this effect was involved in the
changes in plasma SIV RNA and cell-associated viral
load that occurred after SIVIG infusion. Of note is that
changes in cell-associated viral load have been normal-
ized for T-cell count, since they are recorded as units per
million lymphocytes. The explanation of the changes in
T-cell counts is not clear; it could be that an immune
reaction to the infused material stimulates lymphocyte
migration out of the periphery and into secondary lym-
phoid tissues.
Analysis of viral turnover mechanisms in SIVIG-
infused animals
We showed above that a two- to threefold drop in the
plasma SIV RNA concentration was initiated within 1–2 h
of SIVIG infusion into the rapidly progressing animals
1356 and 191N and was complete within 12 h (Figs. 1 and
2). The half-life of the decrease in plasma viremia in-
duced by the infused antibodies was estimated to be
10 h. In both animals, the viral load began to rebound
within 24 h of SIVIG infusion, but did not fully return to
preinfusion levels within 72 h.
The dynamics of these SIVIG-induced viremia
changes are inconsistent with a significant involvement
of virus-neutralizing antibodies. This is self-evident and
requires no formal proof: Neutralizing antibodies protect
new cells from becoming infected, but newly infected
cells produce virions only after approximately 24 h (Per-
FIG. 4. Effect of RhIG on anti-SIV titers and viral load: monkey R341.
Monkey R341 (a normal progressor) was infused with RhIG at time 0.
(A) Anti-gp120 (E) and anti-p27 () binding antibody titers. (B) Neutral-
ization titers against TCA SIVmac251. (C) Plasma SIV RNA level.
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242 BINLEY ET AL.elson et al., 1996). Hence an interfering effect of neutral-
izing antibodies would be apparent only after this time,
when those cells that were protected from infection
would have begun to release virus to the plasma. In-
stead, plasma viremia started to fall within 1–2 h of SIVIG
infusion, far too soon for the involvement of neutralizing
antibodies. This is perhaps unremarkable, considering
that the primary viruses from these animals are not
appreciably neutralized in in vitro assays.
We next considered whether SIVIG infusion caused an
ncreased rate of virion clearance via immune complex-
ng. To do this, we used the following reasoning.
Prior to SIVIG infusion the viral load is, to a good
pproximation, in steady state. Hence the initial rate of
FIG. 5. Comparison of changes in plasma SIV RNA and cell-associat
xperiments on SIVIG recipients 1356 (Fig. 1) and 191N (Fig. 2) and R
cell-associated viral load (h) are normalized to the value at the time o
FIG. 6. Effect of SIVIG and RhIG infusions on peripheral CD41 and
D81 T-cell counts. Peripheral CD41 (}) and CD81 ({) T-cell counts(cells/ml) were measured in SIVIG recipients 1356 (A) and 191N (B) and
in RhIG recipient 1504 (C) before, during, and after the infusions.virion production, P 1, equals the initial rate of clearance,
C 1. Clearly, when the virus load declines, C . P, and
hen it increases again, P . C. At the nadir of the virus
oad P 5 C once more, although at this time virion
learance is partially mediated by the infused antibody
o the values of P and C have both changed, to P 2 and
C 2.
The rate of virion production, P, is proportional to the
nfected cell load, Y. Thus, P 5 pY, where p is a
roportionality constant. The clearance rate prior to
IVIG infusion is proportional only to the free virus con-
entration, V, since we assume that all factors that con-
ribute to virion clearance before infusion will continue to
o so after infusion. However, after SIVIG infusion, there
s an additional rate of virion clearance due to the in-
used antibody; this is proportional to both V and the
ntibody concentration, A. Thus, the total rate of clear-
nce, C, is represented by the equation
C 5 aAV 1 cV,
here a and c are the proportionality constants for clear-
ance mediated by the infused antibodies and for the
background clearance rate prior to infusion, respectively.
The total rate of change of viral load, R, can therefore
be represented by the equation
R 5 P 2 C,
and hence
R 5 pY 2 aAV 2 cV.
If the decline in plasma viremia were due to immune
complexing, then the effect of the infused antibodies
would primarily be manifested by an increased rate of
free virus clearance; it would not, however, significantly
l load in SIVIG- and RhIG-infused monkeys. The data are derived from
ipient 1504 (Fig. 3). In each panel, the plasma SIV RNA level (n ) and
or RhIG infusion, which is defined as 1.0.ed viraalter the infected cell load during the first few hours after
infusion. This indicates that the virion production rate, P,
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243ANTIBODY INFUSION OF SIV-INFECTED MONKEYSremains the same both before and after SIVIG infusion.
Moreover, prior to infusion the viral load is in steady
state, so P 1 5 C 1. At this time, the concentration of
nfused antibodies, A, equals 0, so P 1 5 cV 1. Immedi-
ately after SIVIG infusion, the antibody concentration
rises to a value defined as A 0. At this instant, the rates of
irion production and clearance have not yet changed.
ence the total rate of change, R, is represented by
R 5 P1 2 cV1 2 aV1A0,
and hence
R 5 2aV1A0,
hich means that the initial rate of viremia decline
quals aA 0.
The experimental data indicate that this initial rate of
ecline corresponds to a virion half-life of 10 h. Hence,
aA0 5 ln2/10~h!,
hich yields a value of 0.06 per hour.
At the nadir of plasma viremia, approximately 12 h
fter SIVIG infusion, the virion production and clearance
ates are still equal, but the concentration of unbound
ntibody has decreased to some level A 2 , A 0. There-
ore we have
R2 5 0 5 pY2 2 aA2V2 2 cV2.
Note that the infected cell load at the nadir is assumed
to be the same as it was prior to SIVIG infusion since
immune complexing will have a negligible effect on virus
production and release during the first 12 h after infusion
(this argument is analogous to that used above for neu-
tralizing antibodies).
The experimental data indicate that the virus load at
the nadir is about half the virus load prior to SIVIG
infusion. Thus, V 2 5 V 1/ 2.
Substituting this into the above equation we obtain
R2 5 0 5 P1 2 aV1/2A2 2 cV1/2,
hich means
R2 5 0 5 cV1 2 aV1/2A1 2 cV1/2,
he solution being c 5 aA 2.
The best available estimates of the minimal rate of free
irus clearance are that, approximately, c 5 0.5 (Igarashi
t al., 1999; Ramratnam et al., 1999; Zhang et al., 1999).
Hence, we have from the initial rate of plasma viremia
decline, aA 0 5 0.06, and from the nadir of the virus load
we have c 5 aA 2 . 0.5. The above equations indicate
that A 2/A 0 . 1, which would mean that the antibody
concentration at the nadir ( A 2) is greater than the anti-ody concentration immediately after SIVIG infusion, A 0.
ince this clearly cannot be true, the conclusion must be
a
shat the experimental measurement of the initial rate of
lasma viremia decline and the observation that a two-
old reduction in plasma viremia occurs over a 10-h
eriod are, when taken together, incompatible with the
ypothesis that the dominant mechanism of the infused
ntibodies is immune complexing.
The rate at which viremia rebounds to the preinfusion
evels is also not compatible with an immune complexing
echanism causing the initial decline. At some time
oint t 5 t 1 shortly after the nadir of virus load is
reached, only a relatively small amount of virus is still
being cleared by the infused antibodies. From this time
point onward, the increase in virus load is, to a good
approximation, given by
Vt 5 V0 2 ~Vt1 2 V0!exp~2c~t 2 t1!!.
Assuming a virion half-life of the 1 h, an increase from,
e.g., 75 to 95% of the preinfusion level would take ap-
proximately 3 h. Again, this value is inconsistent with the
measured rate of the viremia rebound. This takes very
much longer than 3 h in both macaques (Figs. 1 and 2).
Even if there were a minor, residual antiviral effect of
remaining antibody that slowed the kinetics of viral re-
bound, this would not change the overall conclusion. An
immune complexing mechanism is therefore compatible
with neither the rate nor the magnitude of the SIVIG-
induced plasma viremia decline, nor is it compatible with
the rate of viremia rebound to preinfusion levels.
Since the dynamics support neither virus neutraliza-
tion nor immune complexing as a relevant mechanism,
how then does SIVIG infusion cause the initial plasma
viremia decline? One remaining possibility is antibody-
induced death of infected cells, by a process such as
ADCC. Indeed, a reduction in the number of virus-pro-
ducing cells, and hence of virion production, would have
an immediate effect on plasma viremia, because the
rates of free virus clearance and production are so much
greater than the rates of infection and clearance of cells
that the plasma SIV RNA concentration is always, to a
good approximation, proportional to the infected cell
load (Igarashi et al., 1999; Ramratnam et al., 1999; Zhang
et al., 1999). Overall, our analysis strongly supports a
cell-killing mechanism such as ADCC, but not necessar-
ily ADCC, as the principal cause of the transient reduc-
tion of viral load caused by SIVIG infusion.
DISCUSSION
The goal of this study was to investigate whether a
significant pertubation of preexisting antibody titers
could affect plasma viral load. Its principal limitation is
the relatively small number of animals that we were able
to infuse with IgG preparations. A small proportion of
SIVmac251-infected monkeys progress rapidly to disease,ccompanied by low, or no, titers of antibodies to the SIV
tructural proteins (Desrosiers, 1995; Nathanson et al.,
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244 BINLEY ET AL.1999). It was the low endogenous antibody responses in
such animals that underlay the design of this study, since
this factor allowed us to significantly perturb the overall
titer by exogenous infusion of SIVIG. If SIVIG had been
given to animals with normal antibody titers, much less
than a doubling in the total titer could have been
achieved, a factor that is a significant issue when HIVIG
is given to HIV-1-infected humans (Moore, 1998). Another
complication to the use of rapidly progressing monkeys
is that their health is fragile. Prolonged studies of such
animals are not possible; indeed, two additional animals
that we infused with SIVIG or SIVIG-3 F(ab)92 died before
we could obtain meaningful information. Future studies
along these lines would be best carried out using one of
the pathogenic SHIVs, which more reproducibly create
the rapid progressor phenotype (Desrosiers, 1995; Ste-
ger et al., 1998; Dykhuizen et al., 1999; Lu et al., 1999;
Reimann et al., 1999; Nathanson et al., 1999); the prop-
erties of such viruses were not generally known when
we commenced the present study with SIVmac251.
Within the statistical limitations of our study, what can
e conclude from it? The principal finding is that SIVIG
as a very modest effect on viral load, and even this
ffect is only transient. The maximum reduction in
lasma viremia that we measured was approximately
hreefold, which corresponded to an increase in the rate
f virion clearance of between 30 and 50%. Assuming a
iron half-life of 2 h, this corresponds to an additional
learance of 2–5 3 107 particles over the initial 12-h
period when SIVIG had its maximum effect. Thus, even in
circumstances in which significant perturbations of pre-
existing anti-SIV antibody titers could be achieved, vire-
mia was only modestly affected. This observation con-
trasts with the 100- to 1000-fold increases in viral load
caused by depleting CD81 cells from SIVmac251-infected
monkeys (Schmitz et al., 1999; Jin et al., 1999); cellular
mmunity clearly plays the dominant role in controlling
iremia after chronic HIV-1 or SIV infection is established
n the host, whereas antibodies probably contribute rel-
tively little. The conclusions we draw from the present
tudy in a naturally infected host significantly reinforce
hat has been inferred from ex vivo measurements of
ntibody titers or from experiments in murine models
Parren et al., 1999).
We used quasi-heterologous antibodies in this study,
n that the SIVIG-donor animals were infected with the
ame SIVmac251 strain as used to infect the SIVIG recip-
ents. However, the infecting virus will have evolved dif-
erently in the individual animals, especially in the highly
iremic rapid progressors. This means that the donor
ntibodies will not be perfectly matched to the viruses
irculating in the recipient animals at the time of infusion.
hen HIVIG prepared from donor pools is infused into
ther humans infected with HIV-1 strains of limited anti-
enic relatedness, the mismatch between the antibodies
nd the circulating viruses is likely to be very much
wreater than the mismatch in our studies (Cummins et al.,
991; Levy et al., 1994; Vittecocq et al., 1995; Lambert et
al., 1997; Mofenson et al., 1999). Taken together with the
extremely limited increase in total antibody titer that can
be achieved when HIVIG is infused into humans who
have already successfully seroconverted to HIV-1 (Lam-
bert et al., 1997; Moore, 1998), it is not surprising that
there are no clinical benefits of HIVIG infusion (Lambert
et al., 1997; Mofenson et al., 1999). Of note is that HIVIG
stocks were chosen for clinical use on the basis of their
high anti-p24 antibody titers (Mofenson et al., 1999). It is
now clear that for passively infused antibodies to have
any significant effect, even transiently, they must be ca-
pable of potently neutralizing the relevant virus strain,
something that cannot be achieved by anti-p24 antibod-
ies (Igarashi et al., 1999; Shibata et al., 1999).
Truly autologous antibodies, or the few human MAbs
with significant cross-neutralization potency, may have a
greater effect on plasma viremia than we observed, al-
though virus evolution to escape such antibodies would
be likely to occur rapidly. Even the infusion of a combi-
nation of the most potent neutralizing antibodies had
very little effect on postinfection viral load in HIV-1-in-
fected hu-PBL SCID mice, and escape mutants rapidly
emerged whenever there was any significant suppres-
sion of plasma viremia (Poignard et al., 1999). Contrast-
ing effects of antibodies on the rates of virion clearance
were, however, seen in virion-infusion experiments (Iga-
rashi et al., 1999; Zhang et al., 1999). When SIVmac251
particles were infused into uninfected and SIVmac251-
nfected macaques, the presence of anti-SIV antibodies
n the infected animals had little impact on the already
apid rate of virion clearance (Zhang et al., 1999), as did
oinfusion of 2 mg of our SIVIG-3 stock together with
irus particles into uninfected monkeys (Zhang et al.,
999). This is consistent with our observations from ex-
eriments of a different design. However, the presence
f more homologous, and unusually potent, neutralizing
ntibodies did increase the rate of virion clearance by
pproximately fivefold when HIV-1DH12 was infused into
macaques that had seroconverted to SHIVDH12, compared
to the rate of clearance when the infusion was inoculated
into uninfected macaques (Igarashi et al., 1999).
Although SIVIG infusion had little sustained effect on
plasma viremia in SIVmac251-infected macaques, a small
drop (approximately two- to threefold) did occur in both
plasma SIV RNA and cell-associated viral load within the
first 12 h, associated with an increase in virion clearance
rates. This absolute fall in plasma viremia was not a
consequence of SIVmac251 neutralization; it occurred rap-
dly, within 1–2 h of infusion, whereas neutralizing anti-
odies interfere with a new cycle of virus replication and
o could affect virus load only after a lag of about 24 h
Perelson et al., 1996). Furthermore, the SIVIG stocks
ere unable to neutralize the primary SIVmac251 isolates
from the test animals with significant potency in vitro. It
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245ANTIBODY INFUSION OF SIV-INFECTED MONKEYSis not, therefore, surprising that neutralization did not
contribute to the limited antiviral effect of SIVIG infusion
in vivo.
Mathematical analysis of the kinetics of the fall in
plasma viremia shows that this occurred too slowly for
SIVIG to be affecting the rate of virion clearance. Thus,
virions are cleared from plasma with a half-life that
ranges from 10–30 min (Igarashi et al., 1999; Zhang et al.,
1999) to 2 h (Ramratnam et al., 1999), whereas in our
study, plasma viremia halved only after about 12 h. Fur-
thermore, a clearance mechanism that involved immune
complexes could not account for the concomitant drop in
cell-associated viral load after SIVIG infusion. For com-
parison, a study on the clearance of hepatitis B surface
antigen by immune complexing after infusion of mono-
clonal antibodies into a chronically infected chimpanzee
showed that circulating antigen reached its nadir within
30 min (Heijtink et al., 1999). The kinetics of this clear-
ance mechanism differ starkly from what we measured
in SIV-infected macaques. An additional point is that
among the complications of AIDS are dysfunctions within
the reticuloendothelial systems for immune complex
phagocytosis (Bender et al., 1987). This may be relevant
to the different effects of antibody infusion into SIV-
infected macaques and hepatitis B-infected chimpan-
zees. We have suggested previously that such dysfunc-
tions could contribute to hypergammaglobulinemia in
HIV-1-infected humans (Morris et al., 1998).
Although the importance of small, transient decreases
in plasma viremia should probably not be overestimated,
we believe that the most likely explanation for the initial
two- to threefold reduction of plasma viremia after SIVIG
infusion is an effector-mediated action of antiviral anti-
bodies on virus-infected cells. A relevant mechanism
could be ADCC- or antibody-dependent, complement-
mediated cytolysis. Consistent with this idea is that
changes in plasma SIV RNA and cell-associated viral
load occurred in concert. A reduction in the ability of
infected cells to produce SIV would rapidly lead to a
reduction in plasma viremia. Only a minor fraction of the
infused SIVIG must be capable of mediating cell killing
since the antiviral effect lasted only a short time (a few
hours) compared to the half-life of the total immunoglob-
ulin pool (several days). The limited time over which
SIVIG was active probably reflects consumption of the
active fraction of the infused antibodies. For ADCC to
have a major impact on viral load during natural infec-
tion, there would have to be a constant production of
enough endogenous antibody to cope with the load of
virus-infected cells, and these antibodies would need to
have the correct specificity. An elevated level of ADCC
activity in HIV-1-infected humans, measured ex vivo, has
been reported to correlate with delayed disease progres-
sion (Baum et al., 1996; Forthal et al., 1999). It may be
that, in circumstances in which there is no detectable
neutralization activity, ADCC is the predominant antiviraleffect of antibodies. However, to induce the killing of
virus-infected cells, ADCC-mediating antibodies must
first recognize viral antigens in their native forms on the
cell surface. This requirement for the recognition of na-
tive structures is likely to be the same as exists for
virus-neutralizing antibodies and is probably the limiting
factor in the abundance of antibodies with true antiviral
effects, of whatever characteristic. Antibodies that rec-
ognize only nonnative viral antigens will probably medi-
ate neither neutralization nor ADCC (Moore and Ho,
1995; Parren et al., 1997, 1999).
An alternative explanation for what we observed
would be that SIVIG specifically causes a redistribution
of infected cells out of the plasma into lymphoid or
reticuloendothelial tissues and in doing so somehow
reduces the extent to which they release virions. It is not,
however, obvious what mechanism would underlie this
process. We were unable to perform histological exam-
inations of tissue samples from the rapidly progressing
macaques because the fragile health of these animals
precluded any surgical procedures more invasive than
the drawing of small volumes of blood.
An infusion with F(ab)92 fragments of SIVIG was per-
ormed to try to address whether the Fc portion of anti-
odies is important for the viral load reduction, through
n effector-mediated mechanism (Liu et al., 1997). Al-
though no reduction in viral load was measured after the
SIVIG F(ab)92 infusion, the experiment was inconclusive:
he highest plasma concentration of SIVIG F(ab)92 frag-
ents (peak anti-gp120 titer of 1:3,500) was approxi-
ately an order of magnitude lower than was achieved
ith SIVIG, so we could not be certain that the lack of
ffect on viral load was not merely due to an inadequate
ntibody concentration, as opposed to the absence of
he antibody Fc region. Further studies, perhaps in SHIV-
nfected animals, will be required to investigate effector-
ediated mechanisms of killing infected cells.
Although we and others have found that antibody in-
usion into animals or humans with established SIV or
IV-1 infection has little effect on viral load (Gardner et
l., 1995; Lambert et al., 1997; Poignard et al., 1999;
ofenson et al., 1999), this does not mean that antibod-
es cannot be protective in the context of an HIV-1 vac-
ine. Preventing infection from occurring, or limiting the
nitial dissemination of virus within the host by reducing
he inoculum size, are important ways in which an anti-
ody component could contribute to the development of
multivalent vaccine (Burton and Moore, 1998). Indeed,
here are many examples of successful passive protec-
ion experiments, when antibodies of sufficient neutral-
zation potency are provided prior to, or very soon after,
nfection (Prince et al., 1991; Emini et al., 1992; Parren et
l., 1995; Conley et al., 1996; Guaduin et al., 1995, 1997;
aigwood et al., 1996; Piazza et al., 1997; Joag et al.,1999; Mascola et al., 1999; Shibata et al., 1999). In one
study, a SIVIG preparation that did not effectively neu-
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to protect some animals from infection (Van Rompay et
al., 1998).
The design of vaccines able to induce protective an-
tibodies remains a high priority. In contrast, the develop-
ment of antibody-based methods to reduce viral load
postinfection should be of lesser importance, given the
effectiveness of alternative antiviral therapies, the diffi-
culties in manufacturing HIVIG stocks in large quantities,
and the limited increase in antibody titer that can be
achieved when HIVIG is infused into a seropositive indi-
vidual. For example, HIVIG infusion into infected, preg-
nant women is unlikely to increase antibody titers suffi-
ciently to have an impact on maternal–infant HIV-1 trans-
mission. The infusion of potent, cross-neutralizing
human MAbs is a more plausible strategy, especially if
MAbs are given to the exposed infant, although it should
be noted that cheaper, proven alternatives such as
zidovudine or nevirapine are now available (Connor et
al., 1994; Wade et al., 1998; Musoke et al., 1999; Guay et
al., 1999; Marseille et al., 1999).
MATERIALS AND METHODS
Preparation of purified immunoglobulins
Plasma was obtained from rhesus macaques that had
seroconverted normally after infection with SIVmac251 and
then had a typical disease course. The purification of IgG
from the plasma of macaques has been described pre-
viously (McKinney and Parkinson, 1987; Gardner et al.,
1995). Briefly, the immunoglobulin fraction (SIVIG) was
purified from citrated plasma (pH 4.5) by caprylic acid
precipitation (25 ml/ml) and diluted fivefold with 60 mM
sodium acetate. This was pelleted at 10,000 g for 30 min,
and the supernatant was collected, filtered, and diluted
in PBS, pH 7.4. The supernatant was cooled to 4°C and
immunoglobulin was precipitated by 45% ammonium sul-
fate at 5000 g for 15 min. The redissolved antibodies
were extensively dialyzed into a solution of 10% maltose
in water in preparation for infusion into macaques. Con-
trol immunoglobulin preparations (RhIG) were derived
from uninfected macaques by the same procedure.
The purified SIVIG and RhIG preparations were as-
sayed for bacterial endotoxin using the Limulus QCL-
1000 assay (BioWhittaker Inc.); all had endotoxin levels
below the acceptable limit of 5 U/ml. Their purity was
confirmed by SDS–PAGE and Coomassie staining. The
SIVIG and RhIG preparations were also tested in a stan-
dard proliferation assay using freshly prepared human
PBMC, to ensure that they contained no immunostimu-
latory material. Briefly, 2 3 105 PBMC per well were
ncubated for 5 days in a 96-well plate with or without at
:10 dilution of each immunoglobulin preparation, pulsed
3ith 1 mCi of [ H]thymidine (New England Nuclear, Inc.)
or 18 h, and harvested on a Topcount machine (Packardnc). No preparation stimulated [3H]thymidine incorpora-
tion above background levels.
SIV infection of macaques
Rhesus macaques intravenously infected with
SIVmac251 (or in two cases, the closely related SIVmac239
irus) were nonimmunized controls from several vaccine-
r pathogenesis-related studies. Specifically, macaques
356 and 1504 were infected with SIVmac251 grown in
uman PBMC, macaques 191N and R341 were infected
ith SIVmac251 grown in rhesus PBMC, and macaques
AR73 and AR79 were infected with SIVmac239 grown in
rhesus PBMC. Plasma viremia was routinely monitored
by p27 antigen assay, and seroconversion to SIV anti-
gens was tested by ELISA. Rapid progressor animals
that were highly viremic and that also had minimal titers
of anti-SIV antibodies, while retaining a generally good
state of health, were recruited into the present study.
Viral load measurements
Plasma viremia was measured using the Chiron SIV
bDNA assay, which has a sensitivity limit of 10,000 RNA
copies/ml. Cell-associated viral load was determined by
RT-PCR using an adaptation of the technique developed
for HIV-1 (Vesanen et al., 1997).
Determination of binding and neutralizing antibody
titers
Midpoint titers of binding antibodies to SIVmac251
gp120 and p27 were determined by ELISA as described
previously (Moore and Sattentau, 1993; Connor et al.,
1998). Binding antibody titers to both gp120 and p27 are
presented as midpoint titers, i.e., the dilution at which
half-maximal binding to the test antigen occurs. When
SIVIG was tested prior to infusion, the titers reflect what
was present in the original plasma, allowing for volume
adjustments made during SIVIG preparation.
Neutralization assays were carried out by measuring
inhibition of cell killing in CEMx174 cells, or inhibition of
virus replication in mitogen-stimulated PBMC, essen-
tially as described previously (Montefiori et al., 1996;
Langlois et al., 1998). Note that a 50% reduction in cell
killing corresponds to an approximately 90% reduction in
p27 antigen production by SIV-infected cultures (D. C.
Montefiori, unpublished observations).
Both primary and TCA isolates were used in neutral-
ization assays, including primary viruses isolated from
the macaques before or after SIVIG or RhIg infusion. A
primary virus was isolated from animal 1356 7 days
posttreatment using rhesus PBMC and then subse-
quently expanded in rhesus PBMC. The virus from ani-
mal 191N was isolated from plasma prior to SIVIG infu-
sion, by inoculation of CEMx174 cells. Attempts to isolate
this virus in human PBMC yielded a titer insufficient for
neutralization assays. Virus from animal 1504 was iso-
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of human PBMC. Viruses from the original isolation cul-
tures were used in neutralization assays in these last
two cases. TCA SIVmac251 was grown in the H9 cells; this
stock of the virus is highly sensitive to neutralization in
vitro.
SIVIG and RhIG infusion
All animals used in this study were captive-bred rhe-
sus macaques housed in accordance with the American
Association for Accreditation of Laboratory Animal Care
Standards. Prior to treatment, each animal was anesthe-
tized with ketamine HCl at 10 mg/kg. The right or left
saphenous vein region of each animal was shaved and
cleaned before intravenous infusion with either SIVIG or
control RhIG. The time required to complete antibody
infusions was 4–17 min (see Table 2). No side effects,
such as anaphylaxis reactions, were observed during
treatment. Blood samples for lymphocyte subset mea-
surements, plasma bDNA analysis, and anti-SIV binding
and neutralizing antibody titers were collected at time 0
and then at 1, 2, 3, 6, 12, 24, 36, 48 and 72 h postinfusion.
Additional blood samples were collected weekly.
Briefly, six rhesus macaques were treated with either
SIVIG or control RhIG. Two of these macaques, 1356 and
191N, each received SIVIG at 170 mg/kg. One animal,
AR73, was treated with a lower dose of SIVIG, 65 mg/kg.
Another animal, AR79, received a F(ab)92 fragment prep-
aration of SIVIG at 55 mg/kg. Two animals, 1504 and
R341, were infused with the control RhIG preparation at
170 mg/kg. A summary of each infusion experiment is
provided in Table 2.
Measurement of CD41 and CD81 T-cell counts
Peripheral blood CD41 and CD81 T-cell absolute
ounts were determined using Trucount tubes (Becton
ickinson Inc.). Briefly, 50 ml of whole blood was dis-
pensed into Trucount tubes. The blood was incubated for
10 min at room temperature with 10 ml of the antibody
onjugates CD4-PE (Becton Dickinson), CD8-PerCP
Becton Dickinson), or anti-rhesus CD3 (BioSource Inc.)
nd then treated with 450 ml of FACSlyse buffer (Becton
Dickinson) for 10 min at room temperature. The absolute
counts were calculated according to the manufacturer’s
instructions (TruCount Inc.).
Quantitative analysis of virion clearance
To evaluate the rate of virion clearance in response to
SIVIG infusion we performed the following mathematical
analyses, taking into account the fact that virions are
continuously produced throughout the period of experi-
mentation. To calculate the precise amount of virus
cleared in the presence of SIVIG, it is essential to know
the natural half-life of cell-free virions, for which current
estimates range from about 5 min to 2h (Igarashi et al.,1999; Ramratnam et al., 1999; Zhang et al., 1999). Be-
cause of this uncertainty, we have measured the effec-
tiveness of infused SIVIG by determining the percentage
change in the natural virion clearance rate that existed
prior to SIVIG infusion. The greatest effect of antibody
infusion was observed within the first few hours, so we
confined our calculations to the first 12 h postinfusion.
The percentage change in the virion clearance rate is
defined as 100(1 2 P A/P tot), where P A is the total pro-
duction of virus after antibody infusion, and P tot is the
total production of virus that would have occurred had no
antibodies been infused. P A is defined by the area under
the curve multiplied by the clearance rate of free virus.
Similarly, P tot represents the area under the curve in the
bsence of antibody infusion multiplied by the free virus
learance rate. Since both P A and P tot are inversely
roportional to the free virus clearance rate, the ratio
A/P tot is independent of this parameter. Thus the per-
entage increase in virion clearance caused by SIVIG
nfusion is unaffected by inaccuracies in knowledge of
he free virus clearance rate.
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